<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Karyopharm Therapeutics Inc — News on 6ix</title>
<link>https://6ix.com/company/karyopharm-therapeutics-inc</link>
<description>Latest news and press releases for Karyopharm Therapeutics Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Tue, 24 Mar 2026 04:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/karyopharm-therapeutics-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo68358eb078dffbe2df101521.webp</url>
<title>Karyopharm Therapeutics Inc</title>
<link>https://6ix.com/company/karyopharm-therapeutics-inc</link>
</image>
<item>
<title>Karyopharm Announces $30 Million Private Placement with RA Capital</title>
<link>https://6ix.com/company/karyopharm-therapeutics-inc/news/karyopharm-announces-dollar30-million-private-placement-with-ra-capital</link>
<guid isPermaLink="true">https://6ix.com/company/karyopharm-therapeutics-inc/news/karyopharm-announces-dollar30-million-private-placement-with-ra-capital</guid>
<pubDate>Tue, 24 Mar 2026 04:00:00 GMT</pubDate>
<description>NEWTON, Mass., March 24, 2026 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer</description>
</item>
<item>
<title>Karyopharm's Phase 3 SENTRY Trial in Myelofibrosis Met First Co-Primary Endpoint, Demonstrating Statistically Significant Improvement in Spleen Volume Reduction</title>
<link>https://6ix.com/company/karyopharm-therapeutics-inc/news/karyopharms-phase-3-sentry-trial-in-myelofibrosis-met-first-co-primary-endpoint-demonstrating-statistically-significant-improvement-in-spleen-volume-reduction</link>
<guid isPermaLink="true">https://6ix.com/company/karyopharm-therapeutics-inc/news/karyopharms-phase-3-sentry-trial-in-myelofibrosis-met-first-co-primary-endpoint-demonstrating-statistically-significant-improvement-in-spleen-volume-reduction</guid>
<pubDate>Tue, 24 Mar 2026 04:00:00 GMT</pubDate>
<description>– While Similar Symptom Improvement Was Observed Across the Two Arms Relative to Baseline, SENTRY Did Not Meet its Second Co-Primary Endpoint of Abs-TSS – –</description>
</item>
<item>
<title>Karyopharm Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Company Progress</title>
<link>https://6ix.com/company/karyopharm-therapeutics-inc/news/karyopharm-reports-fourth-quarter-full-123000180</link>
<guid isPermaLink="true">https://6ix.com/company/karyopharm-therapeutics-inc/news/karyopharm-reports-fourth-quarter-full-123000180</guid>
<pubDate>Thu, 12 Feb 2026 12:30:00 GMT</pubDate>
<description>Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today reported financial results for the fourth quarter and full year ended December 31, 2025 and highlighted progress on key clinical development programs.</description>
</item>
<item>
<title>Karyopharm to Report Fourth Quarter and Full Year 2025 Financial Results on February 12, 2026</title>
<link>https://6ix.com/company/karyopharm-therapeutics-inc/news/karyopharm-report-fourth-quarter-full-123000257</link>
<guid isPermaLink="true">https://6ix.com/company/karyopharm-therapeutics-inc/news/karyopharm-report-fourth-quarter-full-123000257</guid>
<pubDate>Thu, 05 Feb 2026 12:30:00 GMT</pubDate>
<description>Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced it will report fourth quarter and full year 2025 financial results on Thursday, February 12, 2026. Karyopharm's management team will host a conference call and audio webcast at 8:00 a.m. ET on Thursday, February 12, 2026, to discuss the financial results and other company updates.</description>
</item>
<item>
<title>Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)</title>
<link>https://6ix.com/company/karyopharm-therapeutics-inc/news/karyopharm-therapeutics-reports-inducement-grants-210500815</link>
<guid isPermaLink="true">https://6ix.com/company/karyopharm-therapeutics-inc/news/karyopharm-therapeutics-reports-inducement-grants-210500815</guid>
<pubDate>Mon, 02 Feb 2026 21:05:00 GMT</pubDate>
<description>Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company granted an aggregate of 1,799 restricted stock units (RSUs) to four newly-hired employees. These RSU awards were granted as of January 31, 2026 (the "Grant Date") pursuant to the Company's 2022 Inducement Stock Incentive Plan, as amended, as inducements material to the new employees entering into employment with Karyopharm in accordance with N</description>
</item>
<item>
<title>Karyopharm Announces Preliminary Unaudited 2025 Revenue and Reiterates Expectation of Delivering Potentially Transformative Phase 3 Data in 2026</title>
<link>https://6ix.com/company/karyopharm-therapeutics-inc/news/karyopharm-announces-preliminary-unaudited-2025-120000166</link>
<guid isPermaLink="true">https://6ix.com/company/karyopharm-therapeutics-inc/news/karyopharm-announces-preliminary-unaudited-2025-120000166</guid>
<pubDate>Mon, 12 Jan 2026 12:00:00 GMT</pubDate>
<description>Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced preliminary unaudited fourth quarter and full year 2025 total revenue and U.S. XPOVIO net product revenue estimates and outlined its 2025 achievements and 2026 objectives.</description>
</item>
<item>
<title>Karyopharm to Participate in Baird's Biotech Discovery Series</title>
<link>https://6ix.com/company/karyopharm-therapeutics-inc/news/karyopharm-participate-bairds-biotech-discovery-120000920</link>
<guid isPermaLink="true">https://6ix.com/company/karyopharm-therapeutics-inc/news/karyopharm-participate-bairds-biotech-discovery-120000920</guid>
<pubDate>Mon, 08 Dec 2025 12:00:00 GMT</pubDate>
<description>Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company's senior management team and Dr. Claire Harrison will participate in a virtual fireside chat as part of Baird's Biotech Discovery Series on Wednesday, December 10, 2025 at 12:00 p.m. ET. Dr. Harrison is Professor of Myeloproliferative Neoplasms, Clinical Director at Guy's and St. Thomas' NHS Foundation Trust and a leading international expert</description>
</item>
<item>
<title>Karyopharm to Participate at the Piper Sandler 37th Annual Healthcare Conference</title>
<link>https://6ix.com/company/karyopharm-therapeutics-inc/news/karyopharm-participate-piper-sandler-37th-120000434</link>
<guid isPermaLink="true">https://6ix.com/company/karyopharm-therapeutics-inc/news/karyopharm-participate-piper-sandler-37th-120000434</guid>
<pubDate>Mon, 01 Dec 2025 12:00:00 GMT</pubDate>
<description>Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company's senior management team will participate at the Piper Sandler 37th Annual Healthcare Conference in a fireside chat on Thursday, December 4, 2025 at 10:30 a.m. ET in New York, NY.</description>
</item>
<item>
<title>Karyopharm Reports Third Quarter 2025 Financial Results and Highlights Recent Company Progress</title>
<link>https://6ix.com/company/karyopharm-therapeutics-inc/news/karyopharm-reports-third-quarter-2025-120000271</link>
<guid isPermaLink="true">https://6ix.com/company/karyopharm-therapeutics-inc/news/karyopharm-reports-third-quarter-2025-120000271</guid>
<pubDate>Mon, 03 Nov 2025 12:00:00 GMT</pubDate>
<description>Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today reported financial results for the third quarter ended September 30, 2025 and highlighted progress on key clinical development programs.</description>
</item>
<item>
<title>Karyopharm to Report Third Quarter 2025 Financial Results on November 3, 2025</title>
<link>https://6ix.com/company/karyopharm-therapeutics-inc/news/karyopharm-report-third-quarter-2025-110000972</link>
<guid isPermaLink="true">https://6ix.com/company/karyopharm-therapeutics-inc/news/karyopharm-report-third-quarter-2025-110000972</guid>
<pubDate>Mon, 27 Oct 2025 11:00:00 GMT</pubDate>
<description>Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced it will report third quarter 2025 financial results on Monday, November 3, 2025. Karyopharm's management team will host a conference call and audio webcast at 8:00 a.m. ET on Monday, November 3, 2025, to discuss the financial results and other company updates.</description>
</item>
<item>
<title>Karyopharm Announces Strategic Financing Transactions to Support Growth; Extends Cash Runway Into Second Quarter of 2026, Beyond Expected Top-Line Readout of Phase 3 SENTRY Trial in Myelofibrosis</title>
<link>https://6ix.com/company/karyopharm-therapeutics-inc/news/karyopharm-announces-strategic-financing-transactions-110000146</link>
<guid isPermaLink="true">https://6ix.com/company/karyopharm-therapeutics-inc/news/karyopharm-announces-strategic-financing-transactions-110000146</guid>
<pubDate>Wed, 08 Oct 2025 11:00:00 GMT</pubDate>
<description>Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that it has entered into comprehensive financing and capital structure transactions expected to provide the Company with $100 million of financial flexibility and additional capital, extending the Company's cash runway into the second quarter of 2026 based on the Company's current operating plans.</description>
</item>
<item>
<title>Karyopharm Announces Completion of Enrollment in the Phase 3 SENTRY Trial in Myelofibrosis</title>
<link>https://6ix.com/company/karyopharm-therapeutics-inc/news/karyopharm-announces-completion-enrollment-phase-110000546</link>
<guid isPermaLink="true">https://6ix.com/company/karyopharm-therapeutics-inc/news/karyopharm-announces-completion-enrollment-phase-110000546</guid>
<pubDate>Wed, 10 Sep 2025 11:00:00 GMT</pubDate>
<description>Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that it has completed enrollment in the Phase 3 SENTRY trial, which is evaluating selinexor in combination with ruxolitinib in JAKi-naïve myelofibrosis patients.</description>
</item>
<item>
<title>Karyopharm Reports Second Quarter 2025 Financial Results and Highlights Recent Company Progress</title>
<link>https://6ix.com/company/karyopharm-therapeutics-inc/news/karyopharm-reports-second-quarter-2025-113000318</link>
<guid isPermaLink="true">https://6ix.com/company/karyopharm-therapeutics-inc/news/karyopharm-reports-second-quarter-2025-113000318</guid>
<pubDate>Mon, 11 Aug 2025 11:30:00 GMT</pubDate>
<description>Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today reported financial results for the second quarter ended June 30, 2025 and highlighted progress on key clinical development programs.</description>
</item>
<item>
<title>Karyopharm to Report Second Quarter 2025 Financial Results on August 11, 2025</title>
<link>https://6ix.com/company/karyopharm-therapeutics-inc/news/karyopharm-report-second-quarter-2025-110000194</link>
<guid isPermaLink="true">https://6ix.com/company/karyopharm-therapeutics-inc/news/karyopharm-report-second-quarter-2025-110000194</guid>
<pubDate>Tue, 05 Aug 2025 11:00:00 GMT</pubDate>
<description>Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced it will report second quarter 2025 financial results on Monday, August 11, 2025. Karyopharm's management team will host a conference call and audio webcast at 8:00 a.m. ET on Monday, August 11, 2025, to discuss the financial results and other company updates.</description>
</item>
<item>
<title>Karyopharm to Present at the Jefferies Global Healthcare Conference</title>
<link>https://6ix.com/company/karyopharm-therapeutics-inc/news/karyopharm-present-jefferies-global-healthcare-120000172</link>
<guid isPermaLink="true">https://6ix.com/company/karyopharm-therapeutics-inc/news/karyopharm-present-jefferies-global-healthcare-120000172</guid>
<pubDate>Tue, 03 Jun 2025 12:00:00 GMT</pubDate>
<description>Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company's senior management team is scheduled to present at the Jefferies Global Healthcare Conference on Thursday, June 5, 2025 at 3:10 p.m. ET in New York, NY.</description>
</item>
<item>
<title>Karyopharm to Participate at the 2025 RBC Capital Markets Global Healthcare Conference</title>
<link>https://6ix.com/company/karyopharm-therapeutics-inc/news/karyopharm-participate-2025-rbc-capital-110000105</link>
<guid isPermaLink="true">https://6ix.com/company/karyopharm-therapeutics-inc/news/karyopharm-participate-2025-rbc-capital-110000105</guid>
<pubDate>Mon, 19 May 2025 11:00:00 GMT</pubDate>
<description>Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company's senior management team will participate at the 2025 RBC Capital Markets Global Healthcare Conference in a fireside chat on Wednesday, May 21 at 10:00 a.m. ET in New York, NY.</description>
</item>
<item>
<title>Karyopharm Announces Poster Presentation on Selinexor in Myelofibrosis at the 2025 European Hematology Association Annual Meeting</title>
<link>https://6ix.com/company/karyopharm-therapeutics-inc/news/karyopharm-announces-poster-presentation-selinexor-133100709</link>
<guid isPermaLink="true">https://6ix.com/company/karyopharm-therapeutics-inc/news/karyopharm-announces-poster-presentation-selinexor-133100709</guid>
<pubDate>Wed, 14 May 2025 13:31:00 GMT</pubDate>
<description>Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced its abstract has been selected for a poster presentation at the 2025 European Hematology Association Annual Meeting (EHA) being held June 12-15 in Milan, Italy. The abstract contains data on selinexor monotherapy in a hard-to-treat, heavily pretreated myelofibrosis patient population from the Phase 2 XPORT-MF-035 trial.</description>
</item>
<item>
<title>Karyopharm Reports First Quarter 2025 Financial Results and Announces New Data in Myelofibrosis that Further Suggests Selinexor May Lead to Meaningful Spleen Volume Reduction, Symptom Improvement, Hemoglobin Stabilization and Disease Modification</title>
<link>https://6ix.com/company/karyopharm-therapeutics-inc/news/karyopharm-reports-first-quarter-2025-200500825</link>
<guid isPermaLink="true">https://6ix.com/company/karyopharm-therapeutics-inc/news/karyopharm-reports-first-quarter-2025-200500825</guid>
<pubDate>Mon, 12 May 2025 20:05:00 GMT</pubDate>
<description>Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today reported financial results for the first quarter ended March 31, 2025 and highlighted progress on key clinical development programs.</description>
</item>
<item>
<title>Karyopharm to Report First Quarter 2025 Financial Results on May 12, 2025</title>
<link>https://6ix.com/company/karyopharm-therapeutics-inc/news/karyopharm-report-first-quarter-2025-200500710</link>
<guid isPermaLink="true">https://6ix.com/company/karyopharm-therapeutics-inc/news/karyopharm-report-first-quarter-2025-200500710</guid>
<pubDate>Thu, 08 May 2025 20:05:00 GMT</pubDate>
<description>Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced it will report first quarter 2025 financial results on Monday, May 12, 2025. Karyopharm's management team will host a conference call and audio webcast at 4:30 p.m. ET on Monday, May 12, 2025, to discuss the financial results and other company updates.</description>
</item>
<item>
<title>Karyopharm Announces 1-for-15 Reverse Stock Split</title>
<link>https://6ix.com/company/karyopharm-therapeutics-inc/news/karyopharm-announces-1-15-reverse-134000396</link>
<guid isPermaLink="true">https://6ix.com/company/karyopharm-therapeutics-inc/news/karyopharm-announces-1-15-reverse-134000396</guid>
<pubDate>Mon, 24 Feb 2025 13:40:00 GMT</pubDate>
<description>Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that it will implement a 1-for-15 reverse stock split of the issued shares of the Company's common stock ("Reverse Stock Split"), effective at 5:00 p.m. Eastern Time on February 25, 2025. The Reverse Stock Split was approved by the Company's stockholders at the Company's Special Meeting of Stockholders held on January 30, 2025, with the final ratio subsequentl</description>
</item>
</channel>
</rss>